Publications by authors named "Chrysovalantou Chatzidimitriou"

The significance of serum beta-2 microglobulin (sβm) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβm levels were measured by a radioimmunoassay (upper normal limit 2.

View Article and Find Full Text PDF

Serum ferritin (SF) is frequently elevated in classical Hodgkin lymphoma (cHL). We report on its prognostic significance in an unselected series of 529 cHL patients treated with state-of-the-art therapy. Higher baseline levels correlated with markers of advanced/aggressive disease.

View Article and Find Full Text PDF

Background: R-DA-EPOCH is an effective regimen for PMLBCL, which permits the omission of consolidative radiotherapy in the majority of patients.

Patient: We describe a 27-year-old female patient, who achieved a complete remission after treatment with six cycles of R-DA-EPOCH (up to the final level). At 6 months after the end of treatment, PET/CT revealed an unexpected, diffusely increased FDG uptake by the bone marrow.

View Article and Find Full Text PDF
Article Synopsis
  • Although classical Hodgkin lymphoma (cHL) is generally treatable, 20-30% of patients still face treatment failure, leading to further relapse or progression, especially after therapies like salvage chemotherapy and autologous stem cell transplantation (autoSCT).
  • Recent immunotherapy advancements, including drugs like Brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) such as nivolumab and pembrolizumab, have shown promising results for patients with relapsed/refractory cHL, providing prolonged remissions or disease stabilization even after multiple previous treatments.
  • These newer therapies are being explored for use earlier in treatment protocols, with BV now approved for initial treatment of advanced stages of cHL and ongoing trials
View Article and Find Full Text PDF